163 related articles for article (PubMed ID: 1769705)
1. MHC antigens on human tumors.
Ruiz-Cabello F; Klein E; Garrido F
Immunol Lett; 1991 Aug; 29(3):181-9. PubMed ID: 1769705
[TBL] [Abstract][Full Text] [Related]
2. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells.
Topalian SL; Rivoltini L; Mancini M; Ng J; Hartzman RJ; Rosenberg SA
Int J Cancer; 1994 Jul; 58(1):69-79. PubMed ID: 7516926
[TBL] [Abstract][Full Text] [Related]
4. Altered MHC class I antigens in tumors.
Algarra I; Collado A; Garrido F
Int J Clin Lab Res; 1997; 27(2):95-102. PubMed ID: 9266279
[TBL] [Abstract][Full Text] [Related]
5. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
6. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
[TBL] [Abstract][Full Text] [Related]
7. MHC expression on human tumors--its relevance for local tumor growth and metastasis.
Garrido F; Ruiz-Cabello F
Semin Cancer Biol; 1991 Feb; 2(1):3-10. PubMed ID: 1912516
[TBL] [Abstract][Full Text] [Related]
8. Analysis of HLA expression in human tumor tissues.
Cabrera T; López-Nevot MA; Gaforio JJ; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2003 Jan; 52(1):1-9. PubMed ID: 12536234
[TBL] [Abstract][Full Text] [Related]
9. Selective MHC expression in tumours modulates adaptive and innate antitumour responses.
Rees RC; Mian S
Cancer Immunol Immunother; 1999 Oct; 48(7):374-81. PubMed ID: 10501850
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of class II-restricted T cell responses by costimulatory NK receptors for class I MHC proteins.
Mandelboim O; Davis DM; Reyburn HT; Valés-Gómez M; Sheu EG; Pazmany L; Strominger JL
Science; 1996 Dec; 274(5295):2097-100. PubMed ID: 8953044
[TBL] [Abstract][Full Text] [Related]
11. Effect of invariant chain on major histocompatibility complex class I molecule expression and stability on human breast tumor cell lines.
Lin X; Wang X; Capek HL; Simone LC; Tuli A; Morris CR; Reber AJ; Solheim JC
Cancer Immunol Immunother; 2009 May; 58(5):729-36. PubMed ID: 18828016
[TBL] [Abstract][Full Text] [Related]
12. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
13. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
14. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
[TBL] [Abstract][Full Text] [Related]
15. Analysis of HLA-E expression in human tumors.
Marín R; Ruiz-Cabello F; Pedrinaci S; Méndez R; Jiménez P; Geraghty DE; Garrido F
Immunogenetics; 2003 Feb; 54(11):767-75. PubMed ID: 12618909
[TBL] [Abstract][Full Text] [Related]
16. Relationship between sensitivity to natural killer cells and MHC class-I antigen expression in colon carcinoma cell lines.
Blottière HM; Zennadi R; Burg C; Douillard JY; Meflah K; Le Pendu J
Int J Cancer; 1992 Feb; 50(4):659-64. PubMed ID: 1537634
[TBL] [Abstract][Full Text] [Related]
17. MHC class I antigens, immune surveillance, and tumor immune escape.
Garcia-Lora A; Algarra I; Garrido F
J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
[TBL] [Abstract][Full Text] [Related]
18. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
[TBL] [Abstract][Full Text] [Related]
19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
20. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
